2023 annual financial data

Lyell Immunopharma 2023 Net margin

Direct answer

Net margin was -180,486.15%.

Operating income was -247.01M USD and net income was -234.63M USD.
Operating cash flow was -163.69M USD.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
130,000 USD
Operating income
-247.01M USD
Net income
-234.63M USD
Operating cash flow
-163.69M USD